ribavirin has been researched along with glucagon-like peptide 1 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Clément, AC; Cooper, CL; Crawley, AM; Doyle, MA; Fadzeyeva, E; Fullerton, MD; Hanson, AA; Jacobs, RL; Jeraj, N; Kim, KH; Locatelli, CA; Lorenzen-Schmidt, I; Morrow, NM; Mulvihill, EE; Nguyen, MA; Nunes, JR; O'Dwyer, C; Pulente, SM; Seymour, R; Travis, N; Trzaskalski, NA; van der Veen, JN; Vulesevic, B | 1 |
1 other study(ies) available for ribavirin and glucagon-like peptide 1
Article | Year |
---|---|
Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression.
Topics: Animals; Dipeptidyl Peptidase 4; Endothelial Cells; Glucagon-Like Peptide 1; Glucose; Hepatitis C; Hepatocytes; Mice; Non-alcoholic Fatty Liver Disease; Ribavirin | 2023 |